premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly This is a bit of a contrarian play. After hitting highs over $550 per share in mid-October, ZM is now trading just above $355 -- over 35% cheaper. Although vaccines are rolling out, it could be that remote meetings may still be necessary until late summer. Other competitors have emerged in the space, but the platform of ZM remains the preference. Current operations have allowed them to accumulate over $700 million in cash over the year. We would buy this with a stop-loss at $250, looking for a return to $435 -- over 20% upside. Yield 0% (Analysts’ price target is $435.00)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Stockchase Research Editor: Michael O'Reilly LI is a manufacturer of smart electric SUVs in China, where EV sales there are expected to grow by 40% next year. December deliveries of EVs in general set new records. Sales by LI were up 530% over the year, which is now generating some significant cash flows. The company is heard to be a potential partner with Apple in their EV project. We would buy this with a stop-loss at $20, looking to target $44 -- over 40% upside. Yield 0% (Analysts’ price target is $44.20)

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly With branded outlets like Fatburger and Johnny Rockets, this restaurant franchiser is well known. As vaccines roll out, demand should continue returning for the franchise owners. System wide sales grew over 50% over the quarter with 12 new locations opening, bringing the total to 678 outlets. Another 26 outlets are fully committed for first-half 2021. This is expected to begin adding significantly to cash flows. We would buy this with a stop-loss at $4.00, looking to target $8.00 -- upside of 30%. Yield 0% (Analysts’ price target is $8.00)
COMMENT
2021 outlook This year, he's not optimistic about bonds because they're paying very low yields. He is concerned about inflation. rising rates is the biggest risk--and opportunity--in 2021, and rates will rise inevitably, though he doesn't know when. He's bullish large-caps. A worry is the new strain of Covid, which is demanding a faster vaccination rate. TINA -- there is no alternative -- to stocks. Overall, he's positive about 2021.
DON'T BUY
Airlines continue to struggle and will take much longer than some expect to recover. There are better opportunities in other sectors, like metals. Yes, people want to travel again, but he thinks it will be a long while before people can actually travel, especially for business.
BUY

In the context of carbon tax announcements and the green push in US government Generally, yes, he'd buy this. There is a green push which will benefit NFI in the next couple of years. As for the Covid effect: People riding transit are extremely cautious and practice safety measures like distancing. Secondly, a company called Gatekeeper will take a passenger's body temperature as they board the bus, as applied to kids boarding school buses.

BUY
New Flyer Industries The Covid effect: People riding transit are extremely cautious and practice safety measures like distancing. Secondly, a company called Gatekeeper will take a passenger's body temperature as they board the bus, as applied to kids boarding school buses.
STRONG BUY
China buys a huge amount of steel and iron ore, so this will benefit Stelco and those commodity prices. The current CEO is very good. This has huge upside with strong real estate value. Will produce strong cash flow to the point that he predicts the dividend to return.
BUY
Disclosure: He's a paid consultant for ALY. They are getting close to closing a deal with an Italian bank to create their discount brokerage arm, focusing on education and trading. He hopes there'll be a soft launch in end-March to be followed by a surfacing of value. There's a lot going on in this space.
RISKY
Recently it's jumped from 10 to 17 cents/share. Reason: Covid attacks major organs (lungs, kidneys) and those with gout are particularly vulnerable; XRX has drugs to treat kidneys and uric acid (high levels lead to gout). XRX has two drugs going into phase-3 drug trials. He likes XRX a lot, but it's highly speculative though. XRX could out-license with one of three companies on a share-revenue basis.
PAST TOP PICK
(A Top Pick Dec 27/19, Up 7%) For a real estate company, it has survived well, due to its industrial real estate holdings. He likes it, but doesn't own it now; the space became too uncertain. He bought it for its yield until the pandemic made real estate too uncertain.
PAST TOP PICK
(A Top Pick Dec 27/19, Up 41%) Pays a 6.5% dividend. The price of iron ore will remain strong in the coming year, but he's looking elsewhere.
PAST TOP PICK
(A Top Pick Dec 27/19, Down 49%) They make highly efficient incinerators. The methane gas pollution that other incinerators create is banned in many US states, so Questor fills this gap its cleaner ones. So, there's a huge opportunity in the States, including Texas. The company is work. Further opportunities for the, but especially in garbage dumps.
BUY

Disclosure: He participated in their recent financing. Their backlog has grown a lot, including a recent US$9.9 million solar contract in Maine which amounts to 20% of their market cap. This remains very undervalued. A Brookfield, Algonquin or Boralex could buy this out.

BUY
Disclosure: He's helped with 2-3 of their financings recently. They make a credit-card sized pouch inserted under the skin that produces insulin to reduce extreme high or low insulin levels. That pouch can be used for many other applications in the future. Results are coming soon. SVA has broken out from 30 cents to 70 before the reports. There are strong opportunities for them in the coming year with potential deals with drugmakers and distributors.